Revolutionizing triple-negative metastatic breast cancer treatment: sacituzumab Govitecan's role in advancing chemotherapy.
Zaheer QureshiAbdur JamilFaryal AltafRimsha SiddiqueEeshal FatimaSara DostRichard Scott ZelkowitzShivendra Shah
Published in: Annals of medicine and surgery (2012) (2024)
In conclusion, Sacituzumab Govitecan shows potential as an innovative therapeutic option for breast cancer, particularly in metastatic breast cancer and triple-negative breast cancer, but it warrants additional research.